TY - JOUR
T1 - A Renewed Charter
T2 - Key Principles to Improve Patient Care in Severe Asthma
AU - Menzies-Gow, Andrew
AU - Jackson, David J.
AU - Al-Ahmad, Mona
AU - Bleecker, Eugene R.
AU - Cosio Piqueras, Francisco de Borja G.
AU - Brunton, Stephen
AU - Canonica, Giorgio Walter
AU - Chan, Charles K.N.
AU - Haughney, John
AU - Holmes, Steve
AU - Kocks, Janwillem
AU - Winders, Tonya
N1 - Funding Information:
This manuscript, the Rapid Service Fee, and the Open Access Fee were funded by AstraZeneca (Cambridge, UK). This update to the Charter to Improve Patient Care in Severe Asthma was initiated by AstraZeneca to reflect the evolving views on severe asthma management and to ensure that the Charter remains a relevant tool to explain challenges and solutions for improved care. The revisions to the Charter were debated and refined during two meetings held virtually in November 2021, organised and funded by AstraZeneca. Ten clinicians and patient advocacy representatives attended these meetings.
Funding Information:
Andrew Menzies-Gow has attended advisory boards for AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi, and Teva; has received speaker fees from AstraZeneca, Novartis, Sanofi, and Teva; has participated in research with AstraZeneca for which his institution has been remunerated and has attended international conferences with Teva; and has had consultancy agreements with AstraZeneca and Sanofi. David J. Jackson has received advisory board and speaker fees from AstraZeneca, Sanofi, Novartis, Chiesi Pharmaceuticals, Boehringer Ingelheim, and GlaxoSmithKline (GSK). Mona Al-Ahmad has received advisory board and speaker fees from AstraZeneca, Sanofi, Novartis, and GSK. Eugene Bleecker reports consulting with AstraZeneca, MedImmune, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Regeneron, Sanofi, and Teva. BGC reports personal fees and non-financial support from AstraZeneca during the study; personal fees from GSK; grants from Boehringer; grants and personal fees from Novartis; grants and personal fees from Chiesi; personal fees from Rovi; grants from Menarini; personal fees from Esteve; personal fees from Teva; grants, personal fees, and non-financial support from AstraZeneca; personal fees from ALK; and personal fees from Sanofi, outside the submitted work. Stephen Brunton has served on advisory boards for AstraZeneca and Mylan and has been a speaker for AstraZeneca. Giorgio Walter Canonica has previously received grant or research support from Boehringer Ingelheim, ALK-Abelló, and Stallergenes and honoraria or consultation fees from Menarini, GlaxoSmithKline, Sanofi, Teva, Hal, AstraZeneca, and Novartis. John Haughney has consultancy agreements with AstraZeneca for the PRECISION program and has received consulting or speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, and Teva. Steve Holmes has consultancy agreements with AstraZeneca for the PRECISION program and has received consulting or speaker fees from AstraZeneca, Beximco, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Johnson & Johnson, Mylan, Napp, Novartis, Nutricia, Orion, Pfizer, Sandoz, Teva, and Trudell Medical International. Janwillem Kocks reports grants, personal fees, and non-financial support from AstraZeneca, Boehringer Ingelheim, and GSK; grants and personal fees from Chiesi Pharmaceuticals and TEVA; grants from Valneva; non-financial support from Mundi Pharma; personal fees from MSD and COVIS Pharma outside the submitted work; and holds < 5% shares of Lothar Medtec GmbH and 72.5% of shares in the General Practitioners Research Institute. Tonya Winders has received consulting and speaker fees from AstraZeneca, GlaxoSmithKline, Sanofi, Regeneron, ALK-Abelló, and Novartis.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Asthma is a heterogenous respiratory disease, usually associated with chronic airway inflammation and hyper-responsiveness, which affects an estimated 339 million people worldwide. Severe asthma affects approximately 5–10% of patients with asthma, approximately 17–34 million people globally, more than half of whom have uncontrolled disease. Severe asthma carries a substantial burden of disease, including unpredictable symptoms and potentially life-threatening flare-ups. Furthermore, severe asthma has a substantial burden on health care systems and economies worldwide. In 2018, a group of experts from the clinical community, patient support groups, and professional organisations joined together to develop the Severe Asthma Patient Charter, which set out six principles to define what patients should expect for the management of their severe asthma and what should constitute a basic standard of care. Since the publication of that original Charter in 2018, several important changes have occurred, including an improved understanding of asthma and effective asthma management; several new therapies have become available; and finally, the COVID-19 pandemic has placed a spotlight on respiratory conditions, the workforces that treat them, and the fundamental importance of health care system resilience. With those developments in mind, we, representatives of the academic, clinical, and patient advocacy group communities, have updated the Charter to Improve Patient Care in Severe Asthma with a focus on six principles: (1) I deserve a timely, comprehensive assessment of my asthma and its severity; (2) I deserve a timely, straightforward referral to an appropriate specialist for my asthma when it is not well controlled; (3) I deserve to understand what makes my asthma worse; (4) I deserve access to treatment and care that reduces the impact of asthma on my daily life; (5) I deserve not to be reliant on systemic corticosteroids; (6) I deserve to be involved in decisions about my treatment and care.
AB - Asthma is a heterogenous respiratory disease, usually associated with chronic airway inflammation and hyper-responsiveness, which affects an estimated 339 million people worldwide. Severe asthma affects approximately 5–10% of patients with asthma, approximately 17–34 million people globally, more than half of whom have uncontrolled disease. Severe asthma carries a substantial burden of disease, including unpredictable symptoms and potentially life-threatening flare-ups. Furthermore, severe asthma has a substantial burden on health care systems and economies worldwide. In 2018, a group of experts from the clinical community, patient support groups, and professional organisations joined together to develop the Severe Asthma Patient Charter, which set out six principles to define what patients should expect for the management of their severe asthma and what should constitute a basic standard of care. Since the publication of that original Charter in 2018, several important changes have occurred, including an improved understanding of asthma and effective asthma management; several new therapies have become available; and finally, the COVID-19 pandemic has placed a spotlight on respiratory conditions, the workforces that treat them, and the fundamental importance of health care system resilience. With those developments in mind, we, representatives of the academic, clinical, and patient advocacy group communities, have updated the Charter to Improve Patient Care in Severe Asthma with a focus on six principles: (1) I deserve a timely, comprehensive assessment of my asthma and its severity; (2) I deserve a timely, straightforward referral to an appropriate specialist for my asthma when it is not well controlled; (3) I deserve to understand what makes my asthma worse; (4) I deserve access to treatment and care that reduces the impact of asthma on my daily life; (5) I deserve not to be reliant on systemic corticosteroids; (6) I deserve to be involved in decisions about my treatment and care.
KW - Health care
KW - Patient advocacy
KW - Severe asthma
U2 - 10.1007/s12325-022-02340-w
DO - 10.1007/s12325-022-02340-w
M3 - Comment/Letter to the editor
C2 - 36251167
AN - SCOPUS:85139952677
VL - 39
SP - 5307
EP - 5326
JO - Advances in therapy
JF - Advances in therapy
SN - 0741-238X
ER -